Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis


Published in:
American Journal of Respiratory and Critical Care Medicine

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person’s rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis

Ian M. Balfour-Lynn, Belinda Lees, Pippa Hall, Gillian Phillips, Mohammed Khan, Marcus Flather, and J. Stuart Elborn, on behalf of the CF WISE ( Withdrawal of Inhaled Steroids Evaluation) Investigators*

Department of Paediatric Respiratory Medicine and Clinical Trials & Evaluation Unit, Royal Brompton Hospital, London; National Heart & Lung Institute, Imperial College London, London; and Adult Cystic Fibrosis Unit, Belfast City Hospital, Belfast, United Kingdom

Rationale: Lung inflammation and injury is critical in cystic fibrosis. An ideal antiinflammatory agent has not been identified but inhaled corticosteroids are widely used despite lack of evidence. Objectives: To test the safety of withdrawal of inhaled corticosteroids with the hypothesis this would not be associated with an earlier onset of acute chest exacerbations.

Methods: Multicenter randomized double-blind placebo-controlled trial in 18 pediatric and adult UK centers. Eligibility criteria included age > 6.0 yr, FEV1 > 40%, predicted, and corticosteroid use > 3 mo. During the 2-mo run-in period, all patients received fluticasone; they then took either fluticasone or placebo for 6 mo.

Measurements and Main Results: Fluticasone group: n = 84, median age 14.6 yr, mean (SD) FEV1 76% (18); placebo group: n = 87, median age 15.8 yr, mean (SD) FEV1 76% (18). There was no difference in time to first exacerbation (primary outcome) with hazard ratio (95% confidence interval) of 1.07 (0.68 to 1.70) for fluticasone versus placebo. There was no effect of age, atopy, corticosteroid dose, FEV1, or Pseudomonas aeruginosa status. There was no change in lung function or differences in antibiotic or rescue bronchodilator use. Fewer patients in the fluticasone group withdrew from the study due to lung-related adverse events (9 vs. 15%); with a relative risk (95% confidence interval) of 0.59 (0.23–1.48) fluticasone versus placebo.

Conclusions: In this study population (applicable to 40% of patients with cystic fibrosis in the UK), it appears safe to consider stopping inhaled corticosteroids. Potential advantages will be to reduce the drug burden on patients, reduce adverse effects, and make financial savings.

Keywords: antiinflammatory therapy; inhaled corticosteroids; lung diseases

Lung disease is responsible for much of the morbidity and most of the mortality in cystic fibrosis (CF). Neutrophil-dominated inflammation combined with an exaggerated host response is a major contributor to this lung injury (1). Antiinflammatory therapy is a logical approach to slow down the inevitable deterioration in lung function, (2, 3) but an ideal agent has not yet been identified (4).

Corticosteroids have a wide range of antiinflammatory actions, including several important effects on neutrophils. Oral corticosteroids slow the progression of CF lung disease, but long term use is precluded by unacceptable side effects (5). A systematic review of inhaled corticosteroids (ICS) in CF revealed 10 randomized controlled trials (6 published), which had studied 293 adults and children (6). There was variable methodologic quality, and the conclusion was that there was “no evidence from existing trials to support the practice of prescribing inhaled steroids in cystic fibrosis.”

While the use of ICS may be justified as a form of symptom prophylaxis for those with recurrent wheezing or concomitant asthma (7), there is little evidence to justify their routine use in CF lung disease. Despite this, there has been an increase in the prescribing and use in patients with CF in Europe and the United States. Databases of annual review returns have recorded the ICS use as 36% in the United Kingdom (1994 and 1995 snapshot data) (8) and 26% in North America (1995 snapshot data) (9). More recent data from 2001 entries showed that in the United Kingdom (CF Trust Database) 52% of children and 55% of adults were prescribed ICS, whereas in the United States (Epidemiologic Study of CF) they were given to 41% of children and 48% of adults. The concern over this increased prescribing is that ICS are not necessarily free of adverse effects, although at recommended doses they have an excellent safety record in asthmatic children (10). However, several case series have highlighted the occasional dangers of high-dose ICS causing adrenal failure in asthmatic children (10).

The widespread use of ICS in CF has made it difficult to mount a prospective trial. We therefore took an alternative approach, which was a withdrawal study in patients who were already taking ICS. Nonblinded withdrawal of ICS was used during the initial phase of the large adult Inhaled Steroids in Obstructive Lung Disease in Europe (ISOLDE) trial of ICS in chronic obstructive pulmonary disease (COPD) (11, 12). The aim of our study was to perform a multicenter randomized double-blind placebo-controlled trial to test the feasibility and safety of withdrawal of ICS in children and adults with CF who were already taking them. The main hypothesis was that withdrawing ICS would not be associated with an earlier onset of acute chest exacerbations. A further hypothesis was that specific subgroups of patients (for example, those with atopy) may benefit from them, and if true, this should allow more discriminatory prescribing.

Some of the results of this study have been previously reported in an abstract (13).

METHODS

For additional detail see the expanded METHODS in the online supplement.

Patients

Patients were recruited from 18 CF centers. Eligibility criteria were a diagnosis of CF; age over 6.0 yr; FEV1 > 40% predicted; and use of

(Received in original form November 25, 2005; accepted in final form March 21, 2006)
ICS ≥ 3 mo. Exclusion criteria were use of oral corticosteroids within the previous month or very high-dose ICS. Cases who were eligible for the trial but whom the clinician wished to continue taking ICS were entered as an open label ICS registry group.

The study was approved by the London Multi-Centre Research Ethics Committee, and all local ethics committees.

Procedures

This was a randomized double-blind placebo-controlled withdrawal study of 8-mo duration. There was a 2-mo run-in period during which all patients received fluticasone propionate via a Volumatic spacer (GlaxoSmithKline, Uxbridge, UK). If previously receiving fluticasone the dose was unchanged, but if they were previously on budesonide or beclometasone dipropionate, this was switched to fluticasone at a 2:1 ratio. Salbutamol (Ventolin accuhaler with dose counter; GlaxoSmithKline) was used as a rescue bronchodilator. Patients were randomized to continue fluticasone or start placebo using identical metered-dose inhalers via their spacer.

The criterion for early trial withdrawal was progressive deterioration, defined as sustained decline in FEV₁ > 15% despite 2 wk of oral/intravenous antibiotics, or sustained symptoms that required restarting ICS or starting oral corticosteroids. The stopping rule for the study was evidence of harm in the placebo group, defined as an excess of patients with acute bronchospasm requiring hospitalization or oral corticosteroids.

Outcome Measures

The primary outcome was time to first respiratory exacerbation using a standard definition (14). Secondary outcomes were: (1) Decline in lung function (spirometry FEV₁ and FVC). (2) New (unplanned) courses of oral or intravenous antibiotics. (3) Rescue bronchodilator usage (from accuhaler dose counter). Serious adverse events were hospitalizations other than for a pulmonary exacerbation. Prespecified subgroup analysis was performed for age, atopic status, dose of ICS, baseline FEV₁, and Pseudomonas aeruginosa infection status.

Randomization and Stratification

Randomization was performed in permuted blocks of four to balance the stratifying variables and centers. Patients were stratified for age, FEV₁, and atopic status. All study personnel and participants were blinded to treatment allocation. Interim analysis (blinded to group allocation) was performed on three occasions for the Data Monitoring Committee.

Statistical Analysis

A treatment withdrawal trial is not easily categorized as either a difference or a noninferiority trial. One would not expect the treatments to be identical, but rather to show that withdrawal was not associated with significant clinical deterioration or critical safety issues. Methodology for such trials is not well established, so the protocol was designed to follow a conventional model. Sample size was based on the primary outcome. We anticipated an exacerbation (event) rate of 70% in 6 mo. Proportional differences of 30% in this event rate are clinically important (reduction in event rate from 70 to 49%; under a proportional hazards assumption this is equivalent to a hazard ratio of 0.56). Sample size estimates (80% power, α = 0.05) for an event rate of 70% indicated we would need 164 patients.

Statistical analyses were based on the intention-to-treat principle and were performed using SAS version 8.1 (SAS Institute Inc., Marlow, UK). All tests were two sided and p values < 0.05 were considered statistically significant. For the primary outcome, the event rates were compared and the hazard ratio with 95% confidence interval (CI) calculated from the Cox proportional hazard model. Wilcoxon rank sum test was used to compare percent change in lung function between the two groups. Odds ratio or relative risks with 95% CI were calculated to compare each categorical variable between the two treatment groups.

RESULTS

Baseline Data

Figure 1 shows the trial profile for recruitment and randomization (November 2001 to July 2004). Baseline characteristics of the 171 randomized patients were well matched (Table 1), but although atopic status was similar in the two groups (as expected because this was in the stratification), there were a greater proportion of asthmatics in the group assigned to fluticasone (25 vs. 9%). Table 1 also shows details of ICS therapy at the time of recruitment. There was a greater proportion taking high-dose ICS in those randomized to fluticasone (55 vs. 45%). During the run-in period, 45% of patients were switched to fluticasone, with similar proportions in both groups. There was no change in lung function from the start of the study (visit 1) to start of study drug (visit 2) in either group—mean difference (95% CI) FEV₁ +0.9% (−0.9 to 2.7) for fluticasone and −1.46% (−3.7 to 0.8) for placebo.

Primary Outcome

There was no difference in time to first exacerbation between the groups, and intention-to-treat analysis showed a hazard ratio (95% CI) of 1.07 (0.68 to 1.70) for fluticasone versus placebo (Figure 2). Per protocol analysis gave a hazard ratio (95% CI) of 1.10 (0.70–1.75). By 6 mo, 49% of the fluticasone group and 46% of the placebo group had experienced at least one chest exacerbation (an absolute difference of 3% with 95% CI of −12 to 18% and a proportional difference of 7%). Eleven patients in the fluticasone group and 14 in the placebo group had two exacerbations whereas 5 in the fluticasone and 8 in the placebo had three or more.

Prespecified Subgroup Analysis for the Primary Outcome

Hazard ratios for time to first exacerbation for fluticasone versus placebo were not significant (using discrete variables) when analyzed by age (p = 0.8), atopic status (p = 0.53), current dose of inhaled corticosteroids (p = 0.15), baseline FEV₁ (p = 0.053), and P. aeruginosa status (p = 0.24). When FEV₁ was analyzed as a continuous covariate, it was significant for event rate with p = 0.03 (i.e., the lower the FEV₁, the higher the event rate), but not significant for treatment with p = 0.09, (i.e., no difference between those on fluticasone and those on placebo). When age was analyzed as a continuous covariate it was significant for neither event rate nor treatment. Because of the imbalance in asthma between the two groups, asthma was included in the model and the adjusted hazard ratio (95% CI) was 1.03 (0.64–1.65) for fluticasone versus placebo.

Secondary Outcomes

There was no significant change in lung function over time in either group, or any difference between the two groups (Figure 3). There was no difference in the number of courses of oral or intravenous antibiotics prescribed, either in number of patients receiving them or the median number of courses per patient (Table 2). Neither was there any difference in rescue bronchodilator use, either in number of patients using them or median number of doses per patient (Table 2).

Height was measured at the start and end of the study in the pediatric patients; Z score was similar for the two groups at the start (Table 1), and there was no difference in growth over the 8 mo—mean (95% CI) difference in height Z score between groups of 0.04 (−1.1 to 0.2). Microbiology testing at each visit showed that of the patients from whom P. aeruginosa had never been isolated before the study, only one patient (in placebo group) developed it for the first time during the study.

Open Label Inhaled Corticosteroid Group

Compared with the 171 patients that clinicians were prepared to enter into the study, the 24 patients who continued on their original ICS differed in having a greater proportion with asthma.
(p < 0.001), a greater proportion on high-dose ICS (p = 0.05), and lower FEV₁ (p = 0.01) and FVC (p = 0.06). Other characteristics, including atopic status, were similar (Table 1). The exacerbation rate was greater in the open label group (69%) compared with the fluticasone group (49%) but this was not significant (p = 0.11). Oral antibiotics were prescribed to 88% and intravenous antibiotics to 46% of the open label group, which is higher (but not significantly) than the fluticasone group.

**Adverse Events and Study Withdrawals**

Total withdrawals after recruitment were the same in the two groups (24 each) (Figure 1). Of those withdrawing before the start of the study drug, seven withdrew from the fluticasone group for clinical events (five with pulmonary exacerbations, one with malaise with candida infection, and one with pancreatitis) and three withdrew from the placebo group due to clinical events (all had a pulmonary exacerbation). After the start of the study drug (visit 2), there were fewer withdrawals in the fluticasone group compared with the placebo group 10/70 (14%) versus 19/82 (23%). These were almost all due to lung-related adverse events 6/70 (9%) versus 12/82 (15%) with a relative risk (95% CI) of fluticasone versus placebo of 0.59 (0.23–1.48). A similar proportion in both groups received oral corticosteroids for these events (7% fluticasone group, 9% placebo group). Lung-related adverse events simply meant protocol-defined exacerbations; withdrawal was due to a need for oral corticosteroids (5/6 fluticasone group and 7/12 placebo group) or concern from the clinician or patient that the patient was on placebo and that lack of ICS had provoked the exacerbation. The one withdrawal due to an adverse event that was not lung-related was in the placebo group and was due to facial swelling with difficulty swallowing. There were three serious adverse events in the fluticasone group (minor head injury, gallstones, intra-abdominal sepsis) and none in the placebo group. Overall, there were 136 adverse events in the fluticasone group and 161 in the placebo group. For comparison of the fluticasone group versus the placebo group, they were classified as CF pulmonary symptoms (118 vs. 132), CF extrapulmonary symptoms (4 vs. 12), symptoms with no relation to CF (13 vs. 17), and possible study-drug-related oral candidiasis in one patient on fluticasone. There were no deaths.
TABLE 1. BASELINE DATA, INCLUDING INHALED CORTICOSTEROID THERAPY AT TIME OF RECRUITMENT

<table>
<thead>
<tr>
<th></th>
<th>Fluticasone (n = 84)</th>
<th>Placebo (n = 87)</th>
<th>Open label ICS (n = 24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr, median (range)</td>
<td>14.6 (6–48)</td>
<td>15.8 (6–53)</td>
<td>14.8 (7–41)</td>
</tr>
<tr>
<td>Males, % (n)</td>
<td>49 (41)</td>
<td>52 (45)</td>
<td>42 (10)</td>
</tr>
<tr>
<td>Genotype, % (n)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔF508 homozygous</td>
<td>48 (40)</td>
<td>59 (51)</td>
<td>42 (10)</td>
</tr>
<tr>
<td>ΔF508 heterozygous</td>
<td>43 (36)</td>
<td>36 (31)</td>
<td>46 (11)</td>
</tr>
<tr>
<td>Other</td>
<td>9 (8)</td>
<td>5 (5)</td>
<td>12 (3)</td>
</tr>
<tr>
<td>Body mass index, kg/m², mean (SD)</td>
<td>19.9 (3.7)</td>
<td>20.1 (4.0)</td>
<td>19.3 (3.3)</td>
</tr>
<tr>
<td>Height, Z score *</td>
<td>–0.55</td>
<td>–0.39</td>
<td></td>
</tr>
<tr>
<td>Atopy, % (n)</td>
<td>35 (29)</td>
<td>38 (33)</td>
<td>46 (11)</td>
</tr>
<tr>
<td>Asthma, % (n)</td>
<td>25 (21)</td>
<td>9 (8)</td>
<td>67 (16)</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa status, % (n)</td>
<td>62% (52)</td>
<td>65% (56)</td>
<td>70% (16)</td>
</tr>
<tr>
<td>≥2 isolations in last 12 mo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous isolation (not last 12 mo)</td>
<td>27% (23)</td>
<td>26% (22)</td>
<td>26% (6)</td>
</tr>
<tr>
<td>Never isolated</td>
<td>11% (9)</td>
<td>9% (8)</td>
<td>4% (1)</td>
</tr>
<tr>
<td>FEV₁ (% predicted), mean (SD)</td>
<td>76 (18)</td>
<td>76 (18)</td>
<td>67 (14)</td>
</tr>
<tr>
<td>FVC (% predicted), mean (SD)</td>
<td>90 (16)</td>
<td>92 (18)</td>
<td>84 (13)</td>
</tr>
<tr>
<td>Current type ICS, % (n)</td>
<td>13 (11)</td>
<td>13 (11)</td>
<td>13 (3)</td>
</tr>
<tr>
<td>Beclometasone</td>
<td>13 (11)</td>
<td>13 (11)</td>
<td></td>
</tr>
<tr>
<td>Budesonide</td>
<td>32 (27)</td>
<td>32 (28)</td>
<td>25 (6)</td>
</tr>
<tr>
<td>Fluticasone</td>
<td>55 (46)</td>
<td>55 (48)</td>
<td>63 (1)</td>
</tr>
<tr>
<td>Current dose of ICS, % (n)</td>
<td>Low dose</td>
<td>45 (38)</td>
<td>55 (48)</td>
</tr>
<tr>
<td></td>
<td>High dose</td>
<td>55 (46)</td>
<td>45 (39)</td>
</tr>
<tr>
<td>Length of time on ICS, yr, median (range)</td>
<td>5 (1–21)</td>
<td>6 (1–23)</td>
<td>5 (1–11)</td>
</tr>
</tbody>
</table>

High dose ICS was defined as > 800 μg/d budesonide or beclometasone or > 400 μg/d fluticasone; low dose was < 800 μg/d of the former and < 400 μg/d of the latter.

* Height Z score (SD score below or above mean height for age and sex-matched normal population) was measured in pediatric centers only (n = 47 fluticasone, n = 48 placebo).

† Significantly different parameters in open label inhaled corticosteroid (ICS) group (p < 0.05) compared with those enrolled in the active trial (n = 171).

DISCUSSION

This study has shown that during the first 6 mo after stopping ICS therapy, there was no apparent impact (adverse or beneficial), on the onset of acute chest exacerbations, decline in lung function, antibiotic prescribing, or rescue bronchodilator use. Replacing the ICS with placebo was found to be safe as there was no significant increase in lung-related adverse effects leading to withdrawal from the study, nor an increased need for oral corticosteroids. Many patients with CF who are on ICS may no longer need them, but caution is advised due to the nonsignificant increase in lung-related adverse effects seen in the placebo group. Data provided by the UK CF Trust Database has shown that the eligibility criteria of this study applied to almost 40% of the UK CF population (approximately 3,000 patients).

It must be stressed that we are not advocating stopping ICS in all patients, but urging clinicians to assess the need in each individual. If there is objective evidence that a patient benefited when ICS were first started, then it is likely they should be continued on ICS. With nonsignificant tests for interaction, the prespecified subgroup analysis has not provided clear information to help define who are more likely to benefit from ICS. However, there was a significant association between increased exacerbation rate and lower lung function, although this did not quite reach significance in the comparison of the fluticasone and placebo groups. There were patients eligible for the study that the clinicians were not prepared to enroll, due to a belief that they should not stop taking ICS. Their baseline data reveals factors that experienced CF clinicians believe warrant the use of ICS therapy. Compared with the patients entered into the study, they had significantly lower lung function, and significantly more were taking high-dose ICS and were thought to have “CF asthma.” Although CF asthma is difficult to define (7), investigators provided their own definitions, which included reversible obstructive airways, peak flow variability, response to antiasthma therapy, and recurrent wheeze, particularly if symptoms are not accompanied by an obvious infective exacerbation; a family or personal history of atopy supported the diagnosis. Although the number of CF asthmatic patients in our study does not allow us
Are there any problems with the study that mean its conclusions should be doubted? Recruitment was open to potential selection bias, with the concern that clinicians only enrolled patients they thought would not deteriorate off ICS. However, in a withdrawal trial it would be unethical to stop a therapy that was believed to be benefiting a patient. Follow-up of patients that clinicians decided not to recruit has provided information on their characteristics and outcomes. The study was powered for the primary outcome on the assumption that 164 patients were required for a 70% exacerbation rate, but the overall exacerbation rate for subjects turned out to be 47%. In retrospect, the protocol definition of an exacerbation was too strict (14), as most clinicians would not wait for four criteria to be satisfied before instituting therapy. For example, an increase in purulent sputum accompanied by a fall in FEV\textsubscript{1} of more than 10% would almost always lead to a course of antibiotics on the assumption the patient had a chest exacerbation (even though only two criteria of the study definition were satisfied). Only 19% of subjects received neither oral nor intravenous antibiotics, so it can be assumed that up to 81% of subjects actually had a chest exacerbation, as this is the usual cause for prescription of a new course of antibiotics. This is supported by the finding that only 11/123 (9%) of patients receiving oral antibiotics were prescribed them for viral upper respiratory tract infections, whereas all intravenous antibiotics were for chest exacerbations. We would recommend a different definition be used for future trials, perhaps the one derived from the North American Epidemiologic Study of CF (ESCF) data, which for patients 6 yr or older has suggested three out of four of decreased FEV\textsubscript{1}, increased cough frequency, new crackles, and haemoptysis (15). In addition, the patients in the trial on which we based power calculations had lower lung function than in our trial (20% had FEV\textsubscript{1} lower than expected exacerbation rate, the 95% CI around the hazard ratios and the fact the results exclude hazard ratios as large as that prespecified (0.56) in either direction would indicate that a type II error has not lead to our finding that there was no difference in outcomes between the two groups. Although our study had a lower power than originally planned, we believe we have effectively excluded an important clinical difference. Furthermore, we do not believe that any differences in withdrawal rate from pulmonary adverse events between the two groups biased the study results due to differential censoring, as everyone withdrawing for this reason still fulfilled the primary outcome as they had had an exacerbation.

This study supports the conclusion from the Cochrane review that there is evidence of neither benefit nor harm (6). The lack

### Table 2. Secondary Outcomes: Use of Oral/Intravenous Antibiotics, and Rescue Bronchodilators

<table>
<thead>
<tr>
<th></th>
<th>Fluticasone (n = 84)</th>
<th>Placebo (n = 87)</th>
<th>Odds Ratio* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral antibiotics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients prescribed new courses, % (n)</td>
<td>74 (62)</td>
<td>78 (68)</td>
<td>0.96 (0.81–1.12)</td>
</tr>
<tr>
<td>Median (IQR) number of courses per patient (in those who received them)</td>
<td>2 (1–3)</td>
<td>2 (1–3)</td>
<td>1.02 (0.69–1.50)</td>
</tr>
<tr>
<td><strong>Intravenous antibiotics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients prescribed new courses, % (n)</td>
<td>38 (32)</td>
<td>38 (33)</td>
<td>0.87 (0.72–1.07)</td>
</tr>
<tr>
<td>Median (IQR) number of courses per patient (in those who received them)</td>
<td>1 (1–2)</td>
<td>1 (1–2)</td>
<td>1.02 (0.69–1.50)</td>
</tr>
<tr>
<td>Patients who received no new courses of oral or intravenous antibiotics, % (n)</td>
<td>18 (15)</td>
<td>20 (17)</td>
<td>1.02 (0.69–1.50)</td>
</tr>
<tr>
<td><strong>Rescue bronchodilators</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients using, % (n)</td>
<td>50 (42)</td>
<td>61 (61)</td>
<td>0.87 (0.72–1.07)</td>
</tr>
<tr>
<td>Median (IQR) number of doses per patient (in those who used them)</td>
<td>56 (20–133)</td>
<td>66 (13–199)</td>
<td>1.02 (0.69–1.50)</td>
</tr>
</tbody>
</table>

* Odds ratios (95% CI) are shown for fluticasone versus placebo.

**Definition of abbreviation:** IQR = interquartile range.
of proven benefit of ICS may be because clinical trials have failed to provide the evidence for a benefit that does exist. The published trials of ICS have a number of flaws, which include small subject numbers, short treatment periods, inadequate drug dosages, and in one case lack of a placebo group (6). The alternative view is that benefit has not been proven because there is no benefit, and if that is the case, why might that be? Delivering inhaled drugs in sufficient quantities to the airways blocked by viscous mucus may be a factor. Poor inhaler technique, especially in children, can also be a problem. More relevant may be the nature of the airway inflammation in CF. It is predominantly neutrophilic and for other airway conditions in which neutrophils predominate, for example, severe asthma (16) and acute bronchiolitis (17), corticosteroids are also not particularly effective (18, 19). Although there is proven benefit in certain aspects of COPD management, (20), a biopsy study showed that 3 mo of fluticasone did not reduce the neutrophilic inflammation, despite improvement in symptoms and exacerbation rate (21). Budesonide and fluticasone, and to a lesser extent beclometasone, have been shown to prolong neutrophil survival by inhibiting apoptosis, so it might be that ICS are even promoting inflammation in CF airways (22). Conversely, ICS are particularly effective in mild to moderate asthma, with its largely eosinophilic inflammation (16), and ICS enhance apoptosis and the subsequent disposal of eosinophils (23).

Some clinicians take the view that ICS should be used anyway, because there are theoretical reasons why they might be useful and there is no apparent evidence of harm (6). Although it is true that they have been used safely for decades in many thousands of asthmatics, this view cannot be supported, especially with high-dose ICS (note that 52% of patients in this study were on 1,000 μg/d or more beclometasone equivalent). It is increasingly recognized that ICS can lead to significant symptoms related to adrenal suppression (24). There have also been reports of children and adults with CF who developed adrenal insufficiency and sometimes Cushing’s syndrome while taking ICS (400–1,200 μg/d) together with itraconazole for allergic bronchopulmonary aspergillosis, due to cytochrome P450 inhibition (25–27). Growth is also a concern in children on ICS (28, 29), and an unpublished study from Belgium showed a significant slowing in linear growth in children with CF on 1,000 μg/d fluticasone for 1 yr (personal communication, K. De Boeck). There was no difference in growth velocity in the 6 mo of our study among the pediatric patients who were on ICS compared with those who stopped. The Lung Health Study II has revealed that inhaled trimcinolone acetonide given to middle aged and elderly patients with mild to moderate COPD leads to an increased incidence of skin bruising and impaired skin healing, as well as loss of bone mineral density after 3 yr of treatment (30, 31). Concern has been expressed about promotion of infection, due to an apparent increase in new P. aeruginosa acquisition, in an unpublished but well publicized small study of ICS that was halted prematurely (32); because of the small numbers and short time frame it is difficult to know whether the findings of this study were valid. However, a retrospective study of 85 patients under 10 yr found no significant effect of the use of ICS on the risk of early P. aeruginosa acquisition, even for those on higher doses (33). Finally, in a UK General Practice Research Database survey of more than 200,000 people aged 3–90 yr, there seems to be a slight increased risk of cataracts in those taking ICS, but only for those aged over 40 (34). There is no information in CF but it is unlikely to be a problem affecting the current age distribution. It can be seen therefore, that there needs to be proper justification to prescribe ICS, and especially at high doses, as, although safety is likely to be acceptable in CF, if genuine benefit has not been proven then the risk-benefit ratio swings toward risk, however small that may be.

We are not aware of any other studies that have taken the approach of withdrawing a therapy in patients with CF. It is an approach that has been used in studying ICS and long acting β₂-agonists in COPD (12, 35–37). Although some patients declined to participate in the trial, for most the reason was not reluctance to stop a drug they had been using for a while, and in fact most were enthusiastic at the prospect of reducing their daily medications. Polypharmacy is a real problem for patients with CF, especially those with more severe disease, and it is likely that as new drugs are started, others are stopped by the patients. Despite this, clinicians tend to add on more treatments without stopping those that do not seem to be making a difference. It is probable that those who did not wish to stop ICS were those who felt they had benefited from them, and also those who were stable and did not want to change anything.

In conclusion, this study has shown that stopping ICS is not harmful for patients with CF who have been taking them for some years. It is likely that the majority of patients taking them no longer need to do so. We would advocate that the prescribing practice of ICS in a CF patient become more like that for an asthmatic. Justification is needed to start them, reassessment is necessary to see whether they are having an effect (particularly on any tight cough or wheeze), and consideration is always given to reducing the dose or stopping them altogether. We are not suggesting ICS should be stopped in all patients but are unable from this study to offer clear guidance as to who might benefit. Nevertheless, baseline data from our open label group has indicated the sort of patients that experienced CF specialists believe benefit the most. This study has not proven whether starting ICS is beneficial in CF; nor has it answered whether ICS may be beneficial in reducing lung inflammation or slowing the rate of decline in lung function when taken long term. All of these questions would need long, large studies to answer them. However it is hoped this study will lead to a reduction in unnecessary ICS prescribing, which in turn will reduce the drug burden placed on patients, reduce potential adverse effects, and save money for the health services.

Conflict of Interest Statement: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

Acknowledgment: The authors thank the Cystic Fibrosis Trust Clinical Trials Advisory Group for helpful suggestions for trial design, GlaxoSmithKline for providing fluticasone and placebo inhalers, the Cystic Fibrosis Trust Database for 2001 data on use of corticosteroids among UK patients, and all the patients and their families for their time and enthusiasm in participating in the study.

Trial Steering Committee

C. Dezateux (Chair), D. Ashby, I.M. Balfour-Lynn, S. Elborn, D. Empey, B. Lees, M. Flather, C. Wallis, S. Walters.

Independent Data Monitoring Committee


Local Investigators and Pharmacists (Number of Enrolled Patients)

References


16. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopie evaluation of severe asthma: persistent inflammation associ-